Envisioning life-changing therapies for neurodegenerative and cardiorenal diseases

What we do

Our approach

Eikonizo is developing disease-modifying therapies by creating brain penetrant and peripheral small molecules to improve the lives of people impacted by neurodegenerative, cardiorenal and other diseases.

Our Programs

Eikonizo is developing a pipeline of highly selective next-generation small molecule inhibitors of HDAC6, a cytoplasmic lysine deacetylase central to intracellular transport, signaling, proteostasis. Our next-gen HDAC6 inhibitors overcome key limitations of previous generation scaffolds.

Our Programs

Eikonizo is developing a pipeline of highly selective next-generation small molecule inhibitors of HDAC6, a cytoplasmic lysine deacetylase central to intracellular transport, signaling, proteostasis. Our next-gen HDAC6 inhibitors overcome key limitations of previous generation scaffolds.

Validated Mechanism

Dysregulated HDAC6 activity impairs intracellular transport, signaling and proteostasis and contributes to the pathology of multiple diseases. HDAC6 inhibition decreases inflammation, oxidative stress, and fibrosis and improves functional outcomes in multiple in vivo neurodegeneration and cardiorenal disease models.

Validated Mechanism

Dysregulated HDAC6 activity impairs intracellular transport, signaling and proteostasis and contributes to the pathology of multiple diseases. HDAC6 inhibition decreases inflammation, oxidative stress, and fibrosis and improves functional outcomes in multiple in vivo neurodegeneration and cardiorenal disease models.
Read More

Supporting Literature

Compelling evidence supports Eikonizo’s unique approach to HDAC6 inhibition

Supporting Literature

Compelling evidence supports Eikonizo’s unique approach to HDAC6 inhibition
Read More
electron microscopic view
Mechanistically Based

Therapeutic Development

Eikonizo’s unique approach to HDAC6 inhibition is designed to synergistically target the mechanisms of intracellular transport, intracellular signaling and proteostasis (protein homeostasis), key drivers of biology of multiple neurodegenerative and cardiorenal diseases.

Correcting these cellular mechanisms via HDAC6 inhibition may also improve other common pathological disease processes including chronic inflammation, mitochondrial dysfunction and oxidative/nitrosative stress and fibrosis, leading to overall improvements in cellular health and function.

Inhibiting HDAC6 in the brain and peripheral nervous system will preserve axonal transport and reduce aberrant protein aggregation, which together may slow or stop the progression of neurodegenerative disease.

HDAC6 inhibition may also impact the course of peripheral indications by improving the inflammation, oxidative stress, and fibrosis that underly the pathological defects in heart failure, chronic kidney disease and other cardiorenal disorders.

find out more
Our Location
CIC Cambridge
One Main Street, 11th Floor
Cambridge, MA 02142
Tel: 617-302-6817